Page last updated: 2024-09-03

desloratadine and Recrudescence

desloratadine has been researched along with Recrudescence in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chaowattanapanit, S; Choonhakarn, C; Julanon, N	1
Dahlén, B; Dahlén, SE; Gülen, T; Hägglund, H; Nilsson, G; Sander, B	1
Bocheńska-Marciniak, M; Górski, P; Kuna, P; Kupczyk, M; Tworek, D	1

Trials

1 trial(s) available for desloratadine and Recrudescence

Article	Year
The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:3 Topics: Adult; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Interleukin-10; Interleukin-18; Interleukin-4; Interleukins; Loratadine; Male; Recurrence; Rhinitis, Allergic, Seasonal; Sleep Wake Disorders; Time Factors; Transforming Growth Factor beta; Treatment Outcome	2007

Article

Year

The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.

Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:3

Topics: Adult; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Interleukin-10; Interleukin-18; Interleukin-4; Interleukins; Loratadine; Male; Recurrence; Rhinitis, Allergic, Seasonal; Sleep Wake Disorders; Time Factors; Transforming Growth Factor beta; Treatment Outcome

2007

Other Studies

2 other study(ies) available for desloratadine and Recrudescence

Article	Year
The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. International journal of dermatology, 2018, Volume: 57, Issue:4 Topics: Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Remission Induction; Retreatment; Retrospective Studies; Treatment Outcome; Urticaria; Young Adult	2018
Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis. Lancet (London, England), 2014, May-03, Volume: 383, Issue:9928 Topics: Acetates; Adult; Anaphylaxis; Cyclopropanes; Delayed Diagnosis; Drug Therapy, Combination; Epinephrine; Fatigue; Flushing; Histamine Antagonists; Humans; Leukotriene Antagonists; Loratadine; Male; Mastocytosis; Quinolines; Ranitidine; Recurrence; Sulfides	2014

Article

Year

The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.

International journal of dermatology, 2018, Volume: 57, Issue:4

Topics: Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Remission Induction; Retreatment; Retrospective Studies; Treatment Outcome; Urticaria; Young Adult

2018

Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis.

Lancet (London, England), 2014, May-03, Volume: 383, Issue:9928

Topics: Acetates; Adult; Anaphylaxis; Cyclopropanes; Delayed Diagnosis; Drug Therapy, Combination; Epinephrine; Fatigue; Flushing; Histamine Antagonists; Humans; Leukotriene Antagonists; Loratadine; Male; Mastocytosis; Quinolines; Ranitidine; Recurrence; Sulfides

2014